APVO Aptevo Therapeutics Inc

$APVO Look at the data. Someone is going to want Mipletamig. And when a big pharma acts on this and provides upfront cash as part of an out licensing deal, the entire game changes here. We'll get an instant re-rate once the cash issue is solved and then that will be followed with another re-rate based on the actual value in the tech platform (that is currently being overlooked due to cash constraints). Going to get exciting when that overhang is eliminated.

$APVO Aptevo is a classic coiled spring situation. A "coiled spring" biotech setup is a slang term used by investors to describe a micro-cap or small-cap biotechnology stock whose stock price has been severely beaten down, even though its underlying science and clinical pipeline are rapidly improving. The term implies that tension is building. The market is completely ignoring positive clinical data, creating a massive disconnect between the company's low stock price and its high intrinsic value. When the market finally notices—or when a major catalyst occurs—the stock price is expected to "snap" upward violently, like a compressed spring being released.

$APVO Absolutely no one seems to see what they are doing with the recent movement into radiopharmaceuticals and the alliance with Niowave. Are you watching where big pharma is moving? I see a host of M&A activity on the horizon.

$APVO concluded its special meeting with shareholder approval of four proposals, including a new stock incentive plan and charter amendment.

$APVO will be issued US patent number 12,760,116 tomorrow titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)"